Connect with us

Technology

NeoImmuneTech’s New Data at ASCO 2024 Highlights Enhanced Benefits of Combining NT-I7 with Checkpoint Inhibitors (CPI) in Immuno-Oncology

Published

on

Results from study NIT-110 with NT-I7 and CPI combination treatment show median overall survival (mOS) improvements over standard of care treatment in pancreatic cancer and MSS colorectal cancerCorrelative analysis identified potentially predictive protein biomarkers associated with patients experiencing the most clinical benefits from combination treatment of NT-I7 and CPICombination of NT-I7 and oncolytic virus demonstrates clear survival improvement in preclinical glioblastoma results

ROCKVILLE, Md., June 3, 2024 /PRNewswire/ — NeoImmuneTech, Inc. (NIT), a T cell-focused therapeutics company, today announced promising interim results of its major clinical trial NIT-110 of NT-I7 (efineptakin alfa), at the 2024 American Society of Clinical Oncology (ASCO) global meeting held in Chicago, from May 31 to June 4. The company also presented two additional posters at the conference.

NIT-110 is a foundational clinical trial for NT-I7 that aims to confirm the safety and efficacy of combining NT-I7 with pembrolizumab (Keytruda®) in solid tumors. The data presented at ASCO 2024 confirmed that the combination is safe and well-tolerated.

Key findings from NIT-110 include:

Pancreatic cancer – Data showed a median overall survival (mOS) of 11.1 months among the 48 pancreatic cancer patients included in the study. The mOS for pancreatic cancer patients who have received a second-line standard of care treatment is currently known to be 6.1 months[1]. This mOS improvement is particularly noteworthy considering that 93.75% of the patients are receiving the combination treatment as third-line or beyond.MSS colorectal cancer -The mOS for the 50 microsatellite-stable (MSS) colorectal cancer patients was 13.2 months. The mOS for the current standard of care treatment is 10.8 months[2].

These results underscore the improved efficacy of the NT-I7 and Keytruda combination over existing standard of care treatments.

A separate poster from trial NIT-110 revealed a correlative analysis identifying a potentially predictive biomarker. These biomarkers may help identify patient populations more likely to benefit clinically from the NT-I7 and Keytruda combination. NeoImmuneTech is committed to further biomarker validation to enhance clinical outcomes.

Additionally, a preclinical study presented at ASCO 2024 highlighted the combination of NT-I7 with an oncolytic virus (ZIKV) in a glioblastoma animal model. Results demonstrated a significant increase in tumor specific CD8 T cells in the tumor microenvironment, leading to improved survival rates. Furthermore, 80% of cases in the experimental group combining NT-I7 with immune checkpoint inhibitors resulted in complete tumor eradication. NT-I7 continues to show clinical benefits driven by T cell amplification when combined with immune therapies.

NeoImmuneTech’s CEO, Luke Oh, PhD, said: “We are very encouraged by the improved clinical efficacy over standard of care in pancreatic and colorectal cancer, a notoriously difficult to treat cancer. These findings confirm our promising preclinical data and open new pathways to further enhance clinical outcomes. We are actively discussing the next steps with Merck. The results presented at ASCO 2024 confirm our strategy to continue to develop NT-I7 in the larger and high-potential immuno-oncology market.”

Posters references:

Abstract #

Track

Poster board #

Title

2621 (Link)

Developmental Therapeutics -Immunotherapy

100

A Phase 2a study of NT-I7 (efineptakin alfa), a long-acting IL-7, and pembrolizumab to evaluate efficacy, including overall survival, in hard-to-treat MSS-CRC and PDAC gastrointestinal tumors

2563

(Link)

Developmental Therapeutics -Immunotherapy

42

Investigation of a potential protein biomarker signature that may predict clinical benefit of NT-I7 and pembrolizumab in patients with cold gastrointestinal tumors

2043

(Link)

Central Nervous System Tumors

342

Expand and pull: a new treatment paradigm for glioblastoma using a long-acting recombinant interleukin-7 and oncolytic viral therapy

 

About Study NIT-110
NIT-110 is an open label Phase 2a clinical trial supported by Merck that aims to confirm the efficacy of combining NT-I7 with Keytruda in two solid tumors. Early results in 2022 had confirmed the efficacy of the combination in pancreatic cancer and MSS colorectal cancer patients, who are known to be unresponsive to immune checkpoint inhibitors alone. Consequently, 24 and 25 additional patients were recruited for each group, respectively, bringing the total to 48 pancreatic cancer patients and 50 MSS colorectal cancer patients currently undergoing clinical trials. Results presented at ASCO 2024 provide an updated analysis including the original and expansion cohorts.

About NT-I7 (efineptakin alfa) (rhIL-7-hyFc)

NT-I7 (efineptakin alfa) is the only clinical-stage long-acting human IL-7, and is being developed in oncologic and immunologic indications, where T cell amplification and increased functionality may provide clinical benefit. IL-7 is a fundamental cytokine for naïve and memory T cell development and for sustaining immune response to chronic antigens (as in cancer) or foreign antigens (as in infectious diseases). NT-I7 exhibits favorable PK/PD and safety profiles, making it an ideal combination partner. NT-I7 is being studied in multiple clinical trials in solid tumors and as vaccine adjuvant. Studies are being planned for testing in hematologic malignancies, additional solid tumors and other immunology-focused indications.

About NeoImmuneTech, Inc.
NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases. NIT is led by the scientific founder and inventor of NT-I7 (efineptakin alfa) and has a strong executive team with rich industry experience. NIT is expanding rapidly in personnel and operations, as well as partnering with industry and academic leaders to investigate NT-I7 as monotherapy and in combination with various immunotherapeutics. For more information, please visit www.neoimmunetech.com.

Forward-looking Statements

The statements contained herein may contain certain forward-looking statements relating to NeoImmuneTech, Inc. (the “Company”) that are based on its beliefs and expectations about the future. These forward-looking statements are based on a number of assumptions about the future, some of which are beyond the Company’s control and are not a guarantee of future performance or developments. Such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company does not undertake any obligation to update any forward-looking statements to reflect events that occur or circumstances that arise after the date of these documents. Accordingly, you should not place reliance on any forward-looking information or statements contained herein.

Some of the data contained in these documents were obtained from various external sources, and the Company has not independently verified such data. Accordingly, the Company makes no representations as to the accuracy or completeness of the data, and such data involves risks and uncertainties and is subject to change based on various factors.

[1] Wang-Gillam et al. Lancet. 2016. doi:10.1016/S0140-6736(15)00986-1
[2] Prager et al. N Engl J Med. 2023. doi:10.1056/NEJMoa221496

 

View original content:https://www.prnewswire.com/news-releases/neoimmunetechs-new-data-at-asco-2024-highlights-enhanced-benefits-of-combining-nt-i7-with-checkpoint-inhibitors-cpi-in-immuno-oncology-302161746.html

SOURCE The NeoImmuneTech, Inc

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

MemeMax Officially Launches, Introducing a Meme-Native Perpetual Trading Infrastructure

Published

on

By

SEOUL, South Korea, SHANGHAI and NEW YORK, April 21, 2026 /PRNewswire/ — MemeMax, a perpetual decentralized exchange (Perp DEX), has officially launched, positioning itself as a trading infrastructure purpose-built for the meme coin market.

As the memecoin sector has grown into a multi-billion-dollar asset class, the lack of derivatives infrastructure tailored to its unique dynamics has become increasingly evident. MemeMax enters the market aiming to address this gap by offering a perpetual trading environment designed specifically for meme-driven assets.

Major meme assets such as DOGE, PEPE, and WIF have historically exhibited extreme volatility driven by narrative cycles and community participation. However, existing trading platforms have struggled to fully accommodate these characteristics.

Why Traditional Perp DEX Models Fall Short for Meme Markets

Most existing perpetual DEXs were originally designed around assets like Bitcoin (BTC) and Ethereum (ETH), where liquidity depth, relatively stable volatility, and structured price discovery dominate market behavior.

Memecoins operate under a fundamentally different dynamic. Price movements are often driven less by fundamentals and more by narrative momentum, community coordination, and viral attention cycles. These assets tend to experience rapid expansions and collapses, often outpacing the assumptions embedded in traditional oracle and liquidation systems.

Despite this, most platforms continue to apply the same infrastructure across all asset classes—creating a structural mismatch when applied to meme markets. MemeMax takes a different approach:

rather than adapting meme assets to fit existing systems, it introduces a trading infrastructure designed specifically for meme-driven market behavior.

Trading the Full Meme Cycle

MemeMax is designed to enable users to trade across the entire lifecycle of a meme.

Shorting narrative breakdownsEntering early during revival phasesNavigating extreme volatility environments

To support this, the platform’s oracle and liquidation mechanisms are structured with high-volatility, lower-liquidity assets in mind, rather than being retrofitted from BTC-centric models

Redefining Trading as Participation

Another key distinction lies in how MemeMax reframes trading itself.

Rather than viewing trading as isolated execution, MemeMax positions it as continuous participation. On-chain user actions are interconnected within a broader system, where behavior contributes directly to the dynamics of the platform.

This reflects a broader shift in meme markets, where price formation is increasingly influenced not only by liquidity, but also by attention and user participation.

Max Points (MP): A Participation-Based Metric

At the core of the platform is Max Points (MP), a native utility system designed to quantify user engagement beyond simple trading volume.

MP is calculated based on multiple dimensions, including:

Profit and loss (P&L) experienceConsistency of platform activity

Note: Incorporating “time spent in positions” into the calculation is planned as an additional feature in a future update.

By incorporating these factors, MemeMax moves away from purely volume-driven incentive models and introduces a system that captures holistic user participation.

MP is expected to serve as a foundational metric across the ecosystem, with applications in reward distribution, seasonal events, and access to platform features. Early participation is designed to provide compounding advantages as the ecosystem evolves.

Max Points (MP): An Activity Reward System

As part of the platform’s reward system, Max Points (MP) exist to reward users for their activities. To encourage consistent user participation rather than just focusing on trading volume, MP operates on a flexible seasonal basis. Adapting to market trends, each season introduces new objectives and various forms of rewards, such as airdrops, recognizing the broader value of ecosystem participation beyond simple PnL.

Staking (Coming Soon)

The staking feature is currently in preparation and will be officially launched in the future as the platform continues to expand.

REKT Pack (In Preparation)

Additionally, it has been confirmed that a “REKT Pack” is currently in preparation. This feature aims to add a layer of entertainment by playfully sublimating user liquidations into meme culture, turning the unfortunate event of getting “rekt” into an engaging and fun experience for the community.

Seasonal Structure for Continuous Expansion

The platform operates on a continuously live trading environment, complemented by recurring seasonal events.

Each season introduces new participation mechanics and reward structures without resetting existing user data. This allows MemeMax to maintain continuity while continuously evolving alongside market dynamics.

Toward a Dedicated Financial Layer for Meme Markets

As memecoins continue to evolve into a distinct segment of the crypto market—driven by community behavior and narrative cycles—the need for specialized infrastructure has become more apparent.

MemeMax positions itself within this trend by treating memes not simply as speculative assets, but as behavior-driven market primitives, embedding these dynamics directly into its trading architecture.

According to the team, “MemeMax is not just another exchange listing meme assets—it is designed as the financial infrastructure that the meme ecosystem has been missing.”

Now Live and Closed Beta Successfully Concluded

A closed beta test was held on April 14 and successfully concluded with great interest from participants.

MemeMax is now live, with users able to access perpetual trading immediately. Participants can begin accumulating Max Points (MP) through on-chain activity and take part in upcoming seasonal events and reward programs. Early users may benefit from first-mover advantages in MP accumulation, positioning themselves favorably within the platform’s evolving incentive structure.

Learn More

Homepage: https://go.mememax.com/official-ptradeDocs: https://docs.mememax.comX (Twitter): https://x.com/MemeMax_Fi

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/mememax-officially-launches-introducing-a-meme-native-perpetual-trading-infrastructure-302748835.html

SOURCE MemeMax

Continue Reading

Technology

Sonata Software Achieves AWS Migration and Modernization Competency Status

Published

on

By

EAST BRUNSWICK, N.J. and BENGALURU, India, April 21, 2026 /PRNewswire/ — Sonata Software (NSE: SONATSOFTW) (BSE: 532221), a leading AI-first Modernization Engineering company, today announced that it has achieved Amazon Web Services (AWS) Migration and Modernization Competency status.

This designation recognizes Sonata Software’s technical expertise and customer experience in helping enterprises accelerate application migration and modernization on AWS. It also reflects the company’s capabilities in supporting organizations as they modernize critical applications, improve operational efficiency, and build agile, resilient, and scalable digital platforms.

The AWS Migration and Modernization Competency helps customers identify AWS Partners with validated capabilities in migrating and modernizing applications from on-premises environments or other cloud platforms. This designation reflects Sonata Software’s capabilities in supporting customers across transformation initiatives spanning application migration, modernization, and optimization on AWS.

“Achieving the AWS Migration and Modernization Competency is an important milestone for Sonata Software and reflects our continued focus on modernization-led transformation,” said Manu Swami, Chief Technology Officer at Sonata Software. “For many enterprises, application modernization is now central to improving resilience, accelerating software delivery, and creating a more adaptable technology foundation. Our focus is on helping clients reduce technical debt, modernize with engineering rigor, and build platforms that support continuous innovation at scale.”

“Achieving the AWS Migration and Modernization Competency reinforces Sonata Software’s position as a trusted partner for enterprises pursuing large-scale transformation,” said Anthony Lange, Chief Revenue Officer at Sonata Software. “Our clients are looking for modernization programs that move quickly, reduce risk, and deliver visible business impact. This recognition strengthens our ability to take that message to the market and underscores the value we bring in helping customers accelerate outcomes through our partnership with AWS.”

Sonata Software continues to strengthen its AWS-aligned capabilities across cloud migration, application modernization, data transformation, platform engineering, and AI-enabled software delivery. In addition to the AWS Migration and Modernization Competency, Sonata has recently achieved AWS DevOps and Generative AI Competencies, along with key AWS service certifications, further reinforcing its ability to help enterprises simplify complexity, modernize business-critical systems, and derive value from their AWS investments.

About Sonata Software

Sonata Software is an AI-first modernization engineering company that helps enterprises transform legacy systems into intelligent, scalable business platforms. Powered by its Platformation™ framework and Harmoni.AI platform, Sonata delivers AI-led modernization across cloud, data, AI, Dynamics, test automation, and managed services. Headquartered in Bengaluru, India, Sonata has more than $1.2 billion in revenue and 6,400+ AI engineers supporting global delivery across regions including the US, UK, India, Malaysia, Mexico, Australia, DACH, and the Nordics. With deep partnerships across Microsoft, AWS, Salesforce, and Snowflake, Sonata helps Fortune 500 enterprises accelerate innovation, improve efficiency, and drive sustainable growth.

For more information, please visit https://www.sonata-software.com/ 

Photo: https://mma.prnewswire.com/media/2961889/Manu_Swami_CTO_Sonata_Software.jpg
Logo: https://mma.prnewswire.com/media/2681656/5928499/Sonata_Software_logo.jpg

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/sonata-software-achieves-aws-migration-and-modernization-competency-status-302748840.html

SOURCE Sonata Software

Continue Reading

Technology

BELLA+CANVAS Brings Coachella 2026 Merchandise to Life with Immersive “Museum of Merchandise” Experience

Published

on

By

Premium apparel leader transforms festival merch into a living archive of culture, creativity, and self-expression

INDIO, Calif., April 21, 2026 /PRNewswire/ — BELLA+CANVAS, the industry leader in premium blank apparel, successfully concluded its role as the official blank apparel provider for the Coachella Valley Music and Arts Festival 2026 merchandise program, delivering both product and a standout on-site activation across two record-setting festival weekends.

At the heart of Coachella’s merchandise ecosystem, BELLA+CANVAS powered official festival products featuring a custom “printed on BELLA+CANVAS” neck label, giving fans a deeper connection to the garments they take home as wearable memories.

Extending beyond product, the brand introduced a first-of-its-kind immersive installation, “Coachella Merchandise: Then and Now — A Retrospective of Coachella Over the Years”. The design-forward, walk-through experience hosted by BELLA+CANVAS reimagined festival merchandise as both cultural archive and creative canvas. Hundreds of festivalgoers explored “Coachella: Then & Now”, revisiting standout pieces from past years while engaging in live, on-site customization.

At the “Museum of Merchandise” experience, guests were invited to print the vintage Coachella designs onto new BELLA+CANVAS t-shirts and sweatshirts of their choosing, blending past and present through personal style. With eight archival designs and eight premium garment options, attendees created unique combinations that reflected their individuality. Through live customization and past inspiration, the experience transformed nostalgia into one-of-a-kind, wearable pieces tied to each guest’s festival journey.

Across both weekends (April 10–12 and April 17–19), the “Museum of Merchandise” drew strong engagement. From festivalgoers, creators, and a curated network of industry influencers, including screen printers, merch designers, and apparel decorators, the experience was amplified in real time across digital platforms.

“Festival merchandise today is more than something you buy. It’s something you become part of,” said Megan Spire, Executive Vice President of Sales and Marketing, BELLA+CANVAS. “At Coachella, BELLA+CANVAS set out to elevate the role of the blank and show how it serves as the foundation for cultural storytelling, creativity, and identity.”

In addition to festivalgoers, media and partners were also offered exclusive access to guided walkthroughs, behind-the-scenes insights into the evolution of festival merchandise, and conversations at the intersection of fashion, music, and experiential storytelling.

As festival merchandise continues to evolve into a form of cultural currency, BELLA+CANVAS’ presence at Coachella 2026 reinforced its position not only as a supplier but as a defining force behind how those stories are created and worn. 

About BELLA+CANVAS
BELLA+CANVAS is a premium apparel company redefining the role of the “blank” clothing product in modern fashion, retail, and brand storytelling. Known for its elevated quality, on-trend fits, and commitment to innovation, the company partners with leading brands, creators, and cultural institutions to power high-impact merchandise and experiential moments. By combining fashion-forward design with scalable production capabilities, BELLA+CANVAS sits at the intersection of apparel, creativity, and culture while serving as the foundation behind some of today’s most influential branded experiences.

Social:
Instagram: https://www.instagram.com/bellacanvas/ 
LinkedIn: https://www.linkedin.com/company/bellacanvas/

View original content to download multimedia:https://www.prnewswire.com/news-releases/bellacanvas-brings-coachella-2026-merchandise-to-life-with-immersive-museum-of-merchandise-experience-302748108.html

SOURCE BELLA+CANVAS

Continue Reading

Trending